A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)

Powles, T, Brown, J, Larkin, J et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

Metadata

Authors/Creators:
  • Powles, T
  • Brown, J
  • Larkin, J
  • Jones, R
  • Ralph, C ORCID logo https://orcid.org/0000-0001-5581-2987
  • Hawkins, R
  • Chowdhury, S
  • Boleti, E
  • Bhal, A
  • Fife, K
  • Webb, A
  • Crabb, S
  • Geldart, T
  • Hill, R
  • Dunlop, J
  • Hall, PE
  • McLaren, D
  • Ackerman, C
  • Beltran, L
  • Nathan, P
Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, biomarker, SRC, VEGF
Dates:
  • Accepted: 6 January 2016
  • Published (online): 22 January 2016
  • Published: May 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 05 Dec 2018 15:17
Last Modified: 05 Dec 2018 15:17
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/annonc/mdw014
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics